Moshkevich Solomon

PRESIDENT, CLINICALDIAGNOSTICS · SEC CIK 2010019
Advertisement

Buy track record

How this insider's open-market purchases have performed
This insider has no open-market purchases in the records we parsed, so there's no buy track record to score. Their full filing history is below.
Advertisement
Open-market buys
$0
0 trades
Open-market sells
$25.18M
92 trades
Net flow
−$25.18M
Net selling
Total filings
110
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Mar 7, 2025 ΔOwn −0.8%

Moshkevich Solomon sold $170.5K of NTRA, trimming their stake 1%.

−$170.5K
1,200 sh @ $142
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Mar 7, 2025 ΔOwn −1.8%

Moshkevich Solomon sold $386.2K of NTRA, trimming their stake 2%.

−$386.2K
2,700 sh @ $143
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Mar 7, 2025 ΔOwn −1.2%

Moshkevich Solomon sold $245K of NTRA, trimming their stake 1%.

−$245K
1,700 sh @ $144
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Mar 7, 2025 ΔOwn −0.3%

Moshkevich Solomon sold $58K of NTRA.

−$58K
400 sh @ $145
Advertisement
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Feb 7, 2025 ΔOwn −1.1%

Moshkevich Solomon sold $290.1K of NTRA, trimming their stake 1%.

−$290.1K
1,632 sh @ $178
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Jan 31, 2025 ΔOwn −0.8%

Moshkevich Solomon sold $195.4K of NTRA, trimming their stake 1%.

−$195.4K
1,178 sh @ $166
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Jan 31, 2025 ΔOwn −2.9%

Moshkevich Solomon sold $666.8K of NTRA, trimming their stake 3%.

−$666.8K
4,020 sh @ $166
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Jan 31, 2025

Moshkevich Solomon sold $502 of NTRA.

−$502
3 sh @ $167
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Jan 24, 2025 ΔOwn −15%

Moshkevich Solomon sold $4.09M of NTRA, trimming their stake 15%.

−$4.09M
24,799 sh @ $165
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Jan 24, 2025

Moshkevich Solomon sold $10.7K of NTRA.

−$10.7K
62 sh @ $172
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Dec 26, 2024

Moshkevich Solomon sold $316 of NTRA.

−$316
2 sh @ $158
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Dec 26, 2024

Moshkevich Solomon sold $475 of NTRA.

−$475
3 sh @ $158
NTRA
Sell Moshkevich Solomon · PRESIDENT, CLINICALDIAGNOSTICS · Open-market sale · filed Dec 26, 2024 ΔOwn −2.0%

Moshkevich Solomon sold $386.7K of NTRA, trimming their stake 2%.

−$386.7K
2,423 sh @ $160

Frequently asked questions

How is Moshkevich Solomon's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Moshkevich Solomon's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.